Term ends Jul 28, 2028 · High confidence
20-year base term ends Jul 28, 2028
Held by Lipidio Pharmaceuticals Inc.
Filed Jul 13, 2012 as application 13/549,299 · Granted Sep 3, 2013
Base term, 20 years from filing
Today
2008
2028
Clock starts
Jul 28, 2008
Jul 28, 2008
Term ends
Jul 28, 2028
Jul 28, 2028
Granted
Sep 3, 2013
Sep 3, 2013
base term
fee events
Updated Nov 14, 2026 · includes USPTO assignment & status data published Nov 14, 2026 and grant & fee data published Nov 10, 2026 (weekly) · how we know
None
Term adjustment
No prosecution delay on this record.
None
Terminal disclaimer
No disclaimer on this record.
3 of 3
Maintenance fees paid
Three maintenance fees fall due, at 3.5, 7.5 and 11.5 years from grant. This counts the ones the record shows paid.
4
Family applications on record here
Applications sharing this one's continuity chain whose file history this site holds. The family may have others.
This patent's term is its 20-year base term, with no adjustment for prosecution delay. All three maintenance fees are recorded paid; no more fees are due. Confidence: High. from the record
How we calculated this date
One row per rule, each showing its own input and what it did to the date. A step we could not verify says so instead of resolving itself.
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, 20 years from filing | Clock starts Jul 28, 2008, when application PCT/IB2008/002028, the earliest non-provisional in its chain, was filed (this one was filed Jul 13, 2012) | Jul 28, 2028 | High confidence |
| Continuity chain | Every parent in the chain resolved | no change | High confidence |
| Patent term adjustment | None on file | no change | High confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | 3 of 3 maintenance fees paid | In force | High confidence |
| Computed term end | The steps above, in order | Jul 28, 2028 | High confidence |
This family
| US 8,242,286 | In force Aug 2028 | Aug 2028 |
| US 8,524,761 | this patent Jul 2028 | Jul 2028 |
| US 8,980,936 | In force Jul 2028 | Jul 2028 |
3 of 4 applications in this family shown, earliest filings first. The applications whose file history this site holds. The family may have others.
Assignments
Assignment documents as recorded at the USPTO, oldest first, with the reel and frame each was recorded at. A recorded assignment is a filed document, not a statement of current ownership, and the absence of a later one is not evidence that the last one still stands.
| Recorded | Assignor | Assignee | Conveyance |
|---|---|---|---|
| Apr 24, 2013 Reel 30281, frame 433 | Medicis Pharmaceutical Corporation | Goldman Sachs Lending Partners LLC | Security Agreement |
| Sep 25, 2013 Reel 31280, frame 766 | Medicis Pharmaceutical Corporation | Thesan Pharmaceuticals, Inc. | Assignment of Assignor's Interest |
| Jan 10, 2014 Reel 31944, frame 190 | Goldman Sachs Lending Partners LLC | Medicis Pharmaceutical Corporation | Release of Security Interest |
| Jan 10, 2014 Reel 31944, frame 256 | Graceway Pharmaceuticals, LLC | Medicis Pharmaceutical Corporation | Assignment of Assignor's Interest |
| Jan 10, 2014 Reel 31944, frame 308 | Pfizer Inc. | Graceway Pharmaceuticals, LLC | Assignment of Assignor's Interest |
| Jan 10, 2014 Reel 31944, frame 321 | Kolosko, Nicole L.; Li, Jin | Pfizer Inc. | Assignment of Assignor's Interest |
| Jan 9, 2015 Reel 34749, frame 689 | Goldman Sachs Lending Partners, LLC | Barclays Bank PLC, as Successor Agent | Notice of Succession of Agency |
| Jan 29, 2018 Reel 45177, frame 26 | Goldman Sachs Lending Partners LLC | Barclays Bank PLC, as Successor Agent | Corrective Assignment to Correct the Inadvertent Patent Numbers Added Previously Recorded at Reel: 034749 Frame: 0689. Assignor(S) Hereby Confirms the Assignment . |
| Aug 23, 2018 Reel 46687, frame 622 | Thesan Pharmaceuticals, Inc. | GDD Therapeutics, LLC | Assignment of Assignor's Interest |
| Oct 26, 2020 Reel 54209, frame 327 | GDD Therapeutics, LLC; GDD Therapeutics, Inc. | GDD Therapeutics, Inc. | Merger and Change of Name |
| Oct 27, 2020 Reel 54226, frame 49 | GDD Therapeutics, Inc. | Lipidio Pharmaceuticals Inc. | Change of Name |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
What's changing
Jul 2028
Term ends Jul 28, 2028. No further fees fall due before then
Citations
6
later US patents cite this one
That is below the median of utility patents granted in 2013 in our data, the only group it is compared against.
How we rank
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.